Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874637 · ClinicalTrials.gov registry record · NA
FemPulse Therapy First-in-Human Experience
A NA study, sponsored by FemPulse Corporation.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT03874637: Completed NA study, sponsored by FemPulse Corporation.
NCT03874637 is a NA study that has completed, run by FemPulse Corporation. The registered enrollment target is 15 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03874637, a NA study, has completed, sponsored by FemPulse Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
Primary Outcome
All device- and procedure-related adverse events will be collected and tabulated
Interventions
- DEVICE Sham Control
- DEVICE Treament
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-02-14 |
| Est. Completion | 2017-05-17 |
| Phase | NA |
What the finished NCT03874637 record still lists
NCT03874637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Sham Control is the first listed.
NCT03874637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03874637 about?
NCT03874637 is a clinical study titled "FemPulse Therapy First-in-Human Experience". The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
What is the current status of trial NCT03874637?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2017-02-14. Estimated completion is 2017-05-17.
What interventions are being tested in trial NCT03874637?
The interventions under investigation include: Sham Control (DEVICE), Treament (DEVICE).
Who is sponsoring clinical trial NCT03874637?
This trial is sponsored by FemPulse Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03874637's enrollment target sits among peer trials
15 1881st of 2000 higher than 92 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI